Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M133Revenue $M11.3Net Margin (%)-207.9Z-Score-6.9
Enterprise Value $M73.9EPS $-0.4Operating Margin %-215.7F-Score1
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-207.9Higher ROA y-yN
Price/Book3.110-y EBITDA Growth Rate %-12.8Quick Ratio3.3Cash flow > EarningsN
Price/Sales11.75-y EBITDA Growth Rate %-14.3Current Ratio3.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-29.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)4ROE % (ttm)-47.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M62.8ROI % (ttm)-23.1Gross Margin Increase y-yN

Gurus Latest Trades with ARQL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARQLJean-Marie Eveillard 2014-12-31 Add$1.06 - $1.36
($1.18)
$ 2.1244%Add 56.31%4,444,899
ARQLGeorge Soros 2014-09-30 Sold Out $1.12 - $1.56
($1.31)
$ 2.1238%Sold Out0
ARQLGeorge Soros 2014-06-30 Buy $1.34 - $2.04
($1.56)
$ 2.1226%New holding78,600
ARQLJean-Marie Eveillard 2013-09-30 Reduce-0.01%$2.15 - $2.79
($2.51)
$ 2.12-18%Reduce -26.47%3,314,553
ARQLJean-Marie Eveillard 2012-12-31 Add0.01%$2.18 - $2.95
($2.6)
$ 2.12-23%Add 49.46%4,539,651
ARQLJean-Marie Eveillard 2012-06-30 Add0.01%$5.53 - $8.16
($6.56)
$ 2.12-209%Add 28.79%2,673,589
ARQLGeorge Soros 2011-12-31 Sold Out -0.0014%$4.58 - $6.05
($5.55)
$ 2.12-162%Sold Out0
ARQLGeorge Soros 2011-09-30 Add$4.11 - $6.64
($5.2)
$ 2.12-145%Add 54.79%16,100
ARQLJean-Marie Eveillard 2011-03-31 Add0.03%$5.85 - $6.95
($6.41)
$ 2.12-202%Add 84.22%1,693,456
ARQLGeorge Soros 2011-03-31 Buy $5.85 - $6.95
($6.41)
$ 2.12-202%New holding12,200
ARQLJean-Marie Eveillard 2010-12-31 Add0.01%$4.95 - $6.14
($5.53)
$ 2.12-161%Add 29.43%919,266
ARQLJean-Marie Eveillard 2010-03-31 Reduce-0.02%$3.04 - $3.92
($3.45)
$ 2.12-63%Reduce -56.47%685,266
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARQL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARQL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ZENNER PATRICK JDirector 2015-03-11Buy10,625$2.32-6.03view
Pucci PaoloCEO 2014-11-20Buy5,000$1.2673.02view
ZENNER PATRICK JDirector 2014-11-14Buy20,830$1.281.67view
Messenger William GDirector 2014-11-14Buy8,500$1.2180.17view
Kelley Susan L.Director 2014-11-13Buy50,000$1.281.67view
Pucci PaoloCEO 2014-09-04Buy5,000$1.3166.41view
Pucci PaoloCEO 2014-05-23Buy5,000$1.455.71view
Pucci PaoloCEO 2014-05-20Buy5,000$1.4253.52view
ZENNER PATRICK JDirector 2014-03-17Buy4,715$2.122.83view
Pucci PaoloCEO 2014-03-13Buy10,000$2.13.81view

Press Releases about ARQL :

    Quarterly/Annual Reports about ARQL:

    News about ARQL:

    Articles On GuruFocus.com
    comment on ARQL Nov 29 2012 
    ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
    ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
    ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
    cooldecency99 note on ARQL May 01 2010 
    ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
    ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
    ArQule Reports Second Quarter 2009 Financial Results Aug 06 2009 
    ArQule, Inc. to Report Second Quarter 2009 Financial Results on Thursday, August 6, 2009 Jul 30 2009 
    ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 


    More From Other Websites
    Roche Acquires CAPP Medical to Strengthen Cancer Diagnosis - Analyst Blog Apr 14 2015
    Pacira Announces Encouraging Data on Lead Drug Exparel - Analyst Blog Apr 13 2015
    Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog Apr 10 2015
    Zacks Rank #1 Additions for Thursday - Tale of the Tape Apr 09 2015
    Shire Reaches Agreement with the FDA for ADHD Candidate - Analyst Blog Apr 08 2015
    ArQule, Inc. to Present at 14th Annual Needham Healthcare Conference Apr 07 2015
    Zacks Rank #1 Additions for Thursday - Tale of the Tape Apr 02 2015
    Receptos, Inc. (RCPT) in Focus: Stock Jumps 5.2% - Tale of the Tape Apr 02 2015
    Akebia Therapeutics (AKBA) in Focus: Stock Slumps 14.4% - Tale of the Tape Apr 02 2015
    Zacks Rank #1 Additions for Friday - Tale of the Tape Mar 13 2015
    Can The Uptrend Continue for ArQule (ARQL)? - Tale of the Tape Mar 12 2015
    ARQULE INC Financials Mar 10 2015
    ArQule (ARQL) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape Mar 09 2015
    10-K for ArQule, Inc. Mar 06 2015
    ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 04 2015
    ArQule Reports Fiscal 2014 Year End and Fourth Quarter Results Mar 04 2015
    ArQule reports 4Q loss Mar 04 2015
    ArQule reports 4Q loss Mar 04 2015
    Q4 2014 ArQule Inc Earnings Release - 07:00 am ET Mar 04 2015
    ArQule Reports Fiscal 2014 Year End and Fourth Quarter Results Mar 04 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK